An Update on Key Areas of Progress In Bladder CancerWe should hear about him. Our MASB Dr. Kamat.
Last year (August 2022), we hadn't reached the minimum threshold of 25 patients @450-days. This year, we should start being in the conversations and in papers.like this one:
Ashish Kamat, MD, MBBS, is a Professor of Urology and Cancer Research and Wayne B. Duddleston Professor of Cancer Research at MD Anderson Cancer Center in Houston, Texas. Dr. Kamat serves as President of International Bladder Cancer Group, (IBCG), and Co-President of International Bladder Cancer Network. The Latest Research on Bladder Cancer - UroToday Urothelial carcinoma remains one of the most common malignancies, with about 81,000 new diagnoses and approximately 17,000 associated deaths in 2022 alone.1 Survival numbers are dependent on early diagnosis and drop with delayed diagnosis and/or advanced stages of disease.1 Both muscle-invasive bladder cancer (MIBC) and non-muscle invasive bladder cancer (NMIBC) are associated with substantial morbidity and reduced quality of life.
READ MORE PREVIOUS ARTICLES